Diana Póvoas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Diana Póvoas has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Fernando Maltez
Faculdade de Medicina Instituto de Saúde Ambiental Universidade de Lisboa Lisbon Portugal
3 shared publications- João Caria
Infectious Diseases Service, Local Health Unity Arrábida, 2910-549 Setúbal, Portugal
2 shared publications Agnieszka Zaleski
Yale Center for Clinical Investigation, Yale University, New Haven, CT, USA
1 shared publicationAlba Grifoni
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA
1 shared publicationAlessandro Sette
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA; Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA, USA
1 shared publicationAna Raquel Pinto
Infectious Diseases Unit, Hospital de Curry Cabral, Unidade Local de Saúde São José, Lisbon, Portugal
1 shared publication
Latest Publications
- Open Access
- 21 January 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1728709
Preventing laboratory-acquired Toxoplasma gondii infection: literature review and case-based post-exposure prophylaxis proposal
Occupationally acquired cases of the intracellular parasite Toxoplasma gondii have been reported, even though there is uncertainty on which infection prevention measures should be implemented in such event. We report a clinical case of laboratory-acquired toxoplasmosis and propose a protocol for post-exposure prophylaxis, given there are no formal guidelines. In this community case study, we describe the management and prevention protocol following an occupational laboratory exposure by a healthy 30-year-old Toxoplasma -seronegative female researcher who suffered an accidental needle puncture with a sample containing a genetically modified hypervirulent Toxoplasma gondii strain. Post-exposure prophylaxis (PEP) with trimethoprim-sulfamethoxazole was implemented for 4 weeks, during which seroconversion occurred, without any accompanying symptoms. Toxoplasma IgM and IgG positivity was observed 21 and 50 days after exposure, respectively, using a validated commercial electrochemiluminescence immunoassay (ECLIA, Roche). Follow-up was maintained for 1 year, during which the patient remained asymptomatic. This report highlights the importance of special care, surveillance and decision on the need for PEP upon occupational laboratory accidental exposure to Toxoplasma gondii . Since there are no guidelines on what the optimal PEP regimen should be, after a literature review, we propose a PEP occupational safety protocol to be implemented in laboratories that handle samples containing Toxoplasma gondii , either in clinical or research setting.
- 21 January 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1728709
Open AccessPreventing laboratory-acquired Toxoplasma gondii infection: literature review and case-based post-exposure prophylaxis proposal
Occupationally acquired cases of the intracellular parasite Toxoplasma gondii have been reported, even though there is uncertainty on which infection prevention measures should be implemented in such event. We report a clinical case of laboratory-acquired toxoplasmosis and propose a protocol for post-exposure prophylaxis, given there are no formal guidelines. In this community case study, we describe the management and prevention protocol following an occupational laboratory exposure by a healthy 30-year-old Toxoplasma -seronegative female researcher who suffered an accidental needle puncture with a sample containing a genetically modified hypervirulent Toxoplasma gondii strain. Post-exposure prophylaxis (PEP) with trimethoprim-sulfamethoxazole was implemented for 4 weeks, during which seroconversion occurred, without any accompanying symptoms. Toxoplasma IgM and IgG positivity was observed 21 and 50 days after exposure, respectively, using a validated commercial electrochemiluminescence immunoassay (ECLIA, Roche). Follow-up was maintained for 1 year, during which the patient remained asymptomatic. This report highlights the importance of special care, surveillance and decision on the need for PEP upon occupational laboratory accidental exposure to Toxoplasma gondii . Since there are no guidelines on what the optimal PEP regimen should be, after a literature review, we propose a PEP occupational safety protocol to be implemented in laboratories that handle samples containing Toxoplasma gondii , either in clinical or research setting.
- Open Access
Mpox in People Living with HIV: Clinical Challenges, Preventive Strategies and Public Health Implications
Monkeypox virus (MPXV) re-emerged in 2022 with a global outbreak that affected more than 100,000 individuals worldwide. People living with HIV (PLWH) accounted for a substantial proportion of cases, raising concerns about disease presentation, management, and outcomes in this population. Evidence indicates that PLWH with advanced or uncontrolled HIV infection experienced more severe mpox, with higher hospitalization rates, more complications, and longer disease courses. In contrast, individuals with well-controlled HIV generally had outcomes similar to those without HIV. Access to timely diagnosis, consistent antiretroviral therapy, and availability of tecovirimat were key factors influencing prognosis. Reports also suggest bidirectional interactions between mpox and HIV pathogenesis. Immune activation and APOBEC3-related viral evolution have been proposed; however, these mechanisms remain incompletely characterized and warrant further investigation. Moreover, disparities in healthcare access and stigma compound the vulnerability of PLWH, emphasizing the need for integrated approaches.
Open AccessMpox in People Living with HIV: Clinical Challenges, Preventive Strategies and Public Health Implications
Monkeypox virus (MPXV) re-emerged in 2022 with a global outbreak that affected more than 100,000 individuals worldwide. People living with HIV (PLWH) accounted for a substantial proportion of cases, raising concerns about disease presentation, management, and outcomes in this population. Evidence indicates that PLWH with advanced or uncontrolled HIV infection experienced more severe mpox, with higher hospitalization rates, more complications, and longer disease courses. In contrast, individuals with well-controlled HIV generally had outcomes similar to those without HIV. Access to timely diagnosis, consistent antiretroviral therapy, and availability of tecovirimat were key factors influencing prognosis. Reports also suggest bidirectional interactions between mpox and HIV pathogenesis. Immune activation and APOBEC3-related viral evolution have been proposed; however, these mechanisms remain incompletely characterized and warrant further investigation. Moreover, disparities in healthcare access and stigma compound the vulnerability of PLWH, emphasizing the need for integrated approaches.
- Top Cited PapersOpen Access
- 28 April 2025
- Published by Elsevier in The Lancet Microbe
- Vol. 6 (7) , 101098
The impact of orthopoxvirus vaccination and Mpox infection on cross-protective immunity: a multicohort observational study
- 28 April 2025
- Published by Elsevier in The Lancet Microbe
- Vol. 6 (7) , 101098
Top Cited PapersOpen AccessThe impact of orthopoxvirus vaccination and Mpox infection on cross-protective immunity: a multicohort observational study
- Open Access
- 28 September 2022
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 38, 21-24
A case of central nervous system infection by Candida famata in an immunosuppressed patient with HIV-1 infection
- 28 September 2022
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 38, 21-24
Open AccessA case of central nervous system infection by Candida famata in an immunosuppressed patient with HIV-1 infection
- 8 October 2021
- Published by Publicacoes Ciencia e Vida, Lda in Portuguese Journal of Nephrology & Hypertension
- Vol. 35 (3)
Infection, immunosuppression, and treatment of auto-immune inflammatory kidney disease
Immunosuppressive drugs are the cornerstone of treatment of auto-immune inflammatory diseases (AIIDs) with renal involvement. How‑ ever, the most commonly used drugs in this setting can increase the risk of bacterial, fungal, and viral infection, and also impair immune response following vaccination. Recommendations and evidence on strategies for infection prevention in the setting of AIIDs treatment will be reviewed.
- 8 October 2021
- Published by Publicacoes Ciencia e Vida, Lda in Portuguese Journal of Nephrology & Hypertension
- Vol. 35 (3)
Infection, immunosuppression, and treatment of auto-immune inflammatory kidney disease
Immunosuppressive drugs are the cornerstone of treatment of auto-immune inflammatory diseases (AIIDs) with renal involvement. How‑ ever, the most commonly used drugs in this setting can increase the risk of bacterial, fungal, and viral infection, and also impair immune response following vaccination. Recommendations and evidence on strategies for infection prevention in the setting of AIIDs treatment will be reviewed.